Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 277 entries
Sorted by: Best Match Show Resources per page
Catheter-based or surgical repair of the highest risk secondary mitral regurgitation patients.

Annals of cardiothoracic surgery

Arsalan M, Squiers JJ, DiMaio JM, Mack MJ.
PMID: 26309831
Ann Cardiothorac Surg. 2015 May;4(3):278-83. doi: 10.3978/j.issn.2225-319X.2015.05.02.

Surgical mitral valve repair (MVR) remains the standard of care for patients with severe valve incompetence with clear, proven benefit for patients with primary mitral regurgitation (MR). Secondary MR is a primary disease of the left ventricular (LV) myocardium....

Cite
Arsalan M, Squiers JJ, DiMaio JM, et al. Catheter-based or surgical repair of the highest risk secondary mitral regurgitation patients. Ann Cardiothorac Surg. 2015;4(3):278-83doi: 10.3978/j.issn.2225-319X.2015.05.02.
Arsalan, M., Squiers, J. J., DiMaio, J. M., & Mack, M. J. (2015). Catheter-based or surgical repair of the highest risk secondary mitral regurgitation patients. Annals of cardiothoracic surgery, 4(3), 278-83. https://doi.org/10.3978/j.issn.2225-319X.2015.05.02
Arsalan, Mani, et al. "Catheter-based or surgical repair of the highest risk secondary mitral regurgitation patients." Annals of cardiothoracic surgery vol. 4,3 (2015): 278-83. doi: https://doi.org/10.3978/j.issn.2225-319X.2015.05.02
Arsalan M, Squiers JJ, DiMaio JM, Mack MJ. Catheter-based or surgical repair of the highest risk secondary mitral regurgitation patients. Ann Cardiothorac Surg. 2015 May;4(3):278-83. doi: 10.3978/j.issn.2225-319X.2015.05.02. PMID: 26309831; PMCID: PMC4533083.
Copy Download .nbib Format: NLM
Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission.

Journal of clinical medicine research

De Vecchis R, Ariano C, Giandomenico G, Di Maio M, Baldi C.
PMID: 27635179
J Clin Med Res. 2016 Oct;8(10):737-42. doi: 10.14740/jocmr2691w. Epub 2016 Aug 30.

BACKGROUND: B-type natriuretic peptide (BNP) is regarded as a reliable predictor of outcome in patients with acute decompensated heart failure (ADHF). However, according to some scholars, a single isolated measurement of serum BNP at the time of hospital admission...

Cite
De Vecchis R, Ariano C, Giandomenico G, et al. Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. J Clin Med Res. 2016;8(10):737-42doi: 10.14740/jocmr2691w.
De Vecchis, R., Ariano, C., Giandomenico, G., Di Maio, M., & Baldi, C. (2016). Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. Journal of clinical medicine research, 8(10), 737-42. https://doi.org/10.14740/jocmr2691w
De Vecchis, Renato, et al. "Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission." Journal of clinical medicine research vol. 8,10 (2016): 737-42. doi: https://doi.org/10.14740/jocmr2691w
De Vecchis R, Ariano C, Giandomenico G, Di Maio M, Baldi C. Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. J Clin Med Res. 2016 Oct;8(10):737-42. doi: 10.14740/jocmr2691w. Epub 2016 Aug 30. PMID: 27635179; PMCID: PMC5012243.
Copy Download .nbib Format: NLM
Thoracic Cavernous Lymphangioma Provoking Massive Chyloptysis: A Case Report.

Journal of investigative medicine high impact case reports

Ferguson R, Hodges J, Harness-Brumley C, Girod C, Bartolome S, DiMaio JM.
PMID: 26425583
J Investig Med High Impact Case Rep. 2013 Sep 11;1(3):2324709613503315. doi: 10.1177/2324709613503315. eCollection 2013.

Chyloptysis is a relatively rare embodiment of disease that encompasses a lengthy differential and provides many diagnostic and therapeutic challenges. Presented here is the case of a young woman with massive chyloptysis due to a thoracic cavernous lymphangioma arising...

Cite
Ferguson R, Hodges J, Harness-Brumley C, et al. Thoracic Cavernous Lymphangioma Provoking Massive Chyloptysis: A Case Report. J Investig Med High Impact Case Rep. 2013;1(3):2324709613503315doi: 10.1177/2324709613503315.
Ferguson, R., Hodges, J., Harness-Brumley, C., Girod, C., Bartolome, S., & DiMaio, J. M. (2013). Thoracic Cavernous Lymphangioma Provoking Massive Chyloptysis: A Case Report. Journal of investigative medicine high impact case reports, 1(3), 2324709613503315. https://doi.org/10.1177/2324709613503315
Ferguson, Robert, et al. "Thoracic Cavernous Lymphangioma Provoking Massive Chyloptysis: A Case Report." Journal of investigative medicine high impact case reports vol. 1,3 (2013): 2324709613503315. doi: https://doi.org/10.1177/2324709613503315
Ferguson R, Hodges J, Harness-Brumley C, Girod C, Bartolome S, DiMaio JM. Thoracic Cavernous Lymphangioma Provoking Massive Chyloptysis: A Case Report. J Investig Med High Impact Case Rep. 2013 Sep 11;1(3):2324709613503315. doi: 10.1177/2324709613503315. eCollection 2013. PMID: 26425583; PMCID: PMC4586815.
Copy Download .nbib Format: NLM
Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

ESMO open

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.
PMID: 28255452
ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016.

In oncology, as in other clinical fields, different treatments are often approved for the same therapeutic indication. In many cases, no direct comparisons are available to inform the choice in clinical practice. In 2015, the Italian Association of Medical...

Cite
Di Maio M, Bruzzi P, Perrone F, et al. Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). ESMO Open. 2016;1(6):e000109doi: 10.1136/esmoopen-2016-000109.
Di Maio, M., Bruzzi, P., Perrone, F., Torri, V., Montemurro, F., Tiseo, M., & Vasile, E. (2016). Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). ESMO open, 1(6), e000109. https://doi.org/10.1136/esmoopen-2016-000109
Di Maio, Massimo, et al. "Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM)." ESMO open vol. 1,6 (2016): e000109. doi: https://doi.org/10.1136/esmoopen-2016-000109
Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E. Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. PMID: 28255452; PMCID: PMC5174803.
Copy Download .nbib Format: NLM
An Unusual Course of Metastatic Gastroesophageal Cancer.

Case reports in oncological medicine

Smith WH, Pintova S, DiMaio CJ, Manolas P, Lee DS, Hiotis SP, Kartsonis M, Holcombe RF, Dharmarajan KV.
PMID: 26770853
Case Rep Oncol Med. 2015;2015:941508. doi: 10.1155/2015/941508. Epub 2015 Dec 03.

We are reporting on a case of a 41-year-old woman who presented with metastatic gastroesophageal junction cancer and who achieved prolonged survival with a multimodal treatment approach. After initially experiencing robust response to chemotherapy, she was treated for distant...

Cite
Smith WH, Pintova S, DiMaio CJ, et al. An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med. 2015;2015:941508doi: 10.1155/2015/941508.
Smith, W. H., Pintova, S., DiMaio, C. J., Manolas, P., Lee, D. S., Hiotis, S. P., Kartsonis, M., Holcombe, R. F., & Dharmarajan, K. V. (2015). An Unusual Course of Metastatic Gastroesophageal Cancer. Case reports in oncological medicine, 2015941508. https://doi.org/10.1155/2015/941508
Smith, William H, et al. "An Unusual Course of Metastatic Gastroesophageal Cancer." Case reports in oncological medicine vol. 2015 (2015): 941508. doi: https://doi.org/10.1155/2015/941508
Smith WH, Pintova S, DiMaio CJ, Manolas P, Lee DS, Hiotis SP, Kartsonis M, Holcombe RF, Dharmarajan KV. An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med. 2015;2015:941508. doi: 10.1155/2015/941508. Epub 2015 Dec 03. PMID: 26770853; PMCID: PMC4681789.
Copy Download .nbib Format: NLM
Quality of life: an important element of treatment value.

The Lancet. Oncology

Di Maio M.
PMID: 29129442
Lancet Oncol. 2017 Dec;18(12):1557-1558. doi: 10.1016/S1470-2045(17)30697-6. Epub 2017 Nov 09.

No abstract available.

Cite
Di Maio M. Quality of life: an important element of treatment value. Lancet Oncol. 2017;18(12):1557-1558doi: 10.1016/S1470-2045(17)30697-6.
Di Maio, M. (2017). Quality of life: an important element of treatment value. The Lancet. Oncology, 18(12), 1557-1558. https://doi.org/10.1016/S1470-2045(17)30697-6
Di Maio, Massimo. "Quality of life: an important element of treatment value." The Lancet. Oncology vol. 18,12 (2017): 1557-1558. doi: https://doi.org/10.1016/S1470-2045(17)30697-6
Di Maio M. Quality of life: an important element of treatment value. Lancet Oncol. 2017 Dec;18(12):1557-1558. doi: 10.1016/S1470-2045(17)30697-6. Epub 2017 Nov 09. PMID: 29129442.
Copy Download .nbib Format: NLM
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Translational lung cancer research

Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S.
PMID: 27413712
Transl Lung Cancer Res. 2016 Jun;5(3):301-21. doi: 10.21037/tlcr.2016.06.10.

Crizotinib is an oral inhibitor of anaplastic lymphoma kinase (ALK) with remarkable clinical activity in patients suffering from ALK-rearranged non-small cell lung cancer (NSCLC), accounting to its superiority compared to chemotherapy. Unfortunately, virtually all ALK-rearranged tumors acquire resistance to...

Cite
Facchinetti F, Tiseo M, Di Maio M, et al. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res. 2016;5(3):301-21doi: 10.21037/tlcr.2016.06.10.
Facchinetti, F., Tiseo, M., Di Maio, M., Graziano, P., Bria, E., Rossi, G., & Novello, S. (2016). Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Translational lung cancer research, 5(3), 301-21. https://doi.org/10.21037/tlcr.2016.06.10
Facchinetti, Francesco, et al. "Tackling ALK in non-small cell lung cancer: the role of novel inhibitors." Translational lung cancer research vol. 5,3 (2016): 301-21. doi: https://doi.org/10.21037/tlcr.2016.06.10
Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res. 2016 Jun;5(3):301-21. doi: 10.21037/tlcr.2016.06.10. PMID: 27413712; PMCID: PMC4931127.
Copy Download .nbib Format: NLM
Physician Burnout: Are We Treating the Symptoms Instead of the Disease?.

The Annals of thoracic surgery

Squiers JJ, Lobdell KW, Fann JI, DiMaio JM.
PMID: 28935298
Ann Thorac Surg. 2017 Oct;104(4):1117-1122. doi: 10.1016/j.athoracsur.2017.08.009.

Despite increasing recognition of physician burnout, its incidence has only increased in recent years, with nearly half of physicians suffering from symptoms of burnout in the most recent surveys. Unfortunately, most burnout research has focused on its profound prevalence...

Cite
Squiers JJ, Lobdell KW, Fann JI, et al. Physician Burnout: Are We Treating the Symptoms Instead of the Disease?. Ann Thorac Surg. 2017;104(4):1117-1122doi: 10.1016/j.athoracsur.2017.08.009.
Squiers, J. J., Lobdell, K. W., Fann, J. I., & DiMaio, J. M. (2017). Physician Burnout: Are We Treating the Symptoms Instead of the Disease?. The Annals of thoracic surgery, 104(4), 1117-1122. https://doi.org/10.1016/j.athoracsur.2017.08.009
Squiers, John J, et al. "Physician Burnout: Are We Treating the Symptoms Instead of the Disease?." The Annals of thoracic surgery vol. 104,4 (2017): 1117-1122. doi: https://doi.org/10.1016/j.athoracsur.2017.08.009
Squiers JJ, Lobdell KW, Fann JI, DiMaio JM. Physician Burnout: Are We Treating the Symptoms Instead of the Disease?. Ann Thorac Surg. 2017 Oct;104(4):1117-1122. doi: 10.1016/j.athoracsur.2017.08.009. PMID: 28935298.
Copy Download .nbib Format: NLM
White light emissions through down-conversion of rare-earth doped LaF(3) nanoparticles.

Optics express

Dimaio JR, Kokuoz B, Ballato J.
PMID: 19529559
Opt Express. 2006 Nov 13;14(23):11412-7. doi: 10.1364/oe.14.011412.

Through the use of complex core-shell structures, white light emissions are observed from a single nanoparticle doped with multiple trivalent rare-earth ions. The internal structuring of the nanoparticle to allow for a controlled degree of energy transfer a common...

Cite
Dimaio JR, Kokuoz B, Ballato J. White light emissions through down-conversion of rare-earth doped LaF(3) nanoparticles. Opt Express. 2006;14(23):11412-7doi: 10.1364/oe.14.011412.
Dimaio, J. R., Kokuoz, B., & Ballato, J. (2006). White light emissions through down-conversion of rare-earth doped LaF(3) nanoparticles. Optics express, 14(23), 11412-7. https://doi.org/10.1364/oe.14.011412
Dimaio, Jeffrey R, et al. "White light emissions through down-conversion of rare-earth doped LaF(3) nanoparticles." Optics express vol. 14,23 (2006): 11412-7. doi: https://doi.org/10.1364/oe.14.011412
Dimaio JR, Kokuoz B, Ballato J. White light emissions through down-conversion of rare-earth doped LaF(3) nanoparticles. Opt Express. 2006 Nov 13;14(23):11412-7. doi: 10.1364/oe.14.011412. PMID: 19529559.
Copy Download .nbib Format: NLM
Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology

Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M.
PMID: 17877484
Hepatol Res. 2007 Sep;37:S206-9. doi: 10.1111/j.1872-034X.2007.00186.x.

AIM: To assess the prognostic ability of the Cancer of the Liver Italian Program (CLIP) score in patients with hepatocellular carcinoma after a longer follow up.METHODS: The updated survival data were derived from an analysis that was performed on...

Cite
Daniele B, Annunziata M, Barletta E, et al. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res. 2007;37:S206-9doi: 10.1111/j.1872-034X.2007.00186.x.
Daniele, B., Annunziata, M., Barletta, E., Tinessa, V., & Di Maio, M. (2007). Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology, 37S206-9. https://doi.org/10.1111/j.1872-034X.2007.00186.x
Daniele, Bruno, et al. "Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma." Hepatology research : the official journal of the Japan Society of Hepatology vol. 37 (2007): S206-9. doi: https://doi.org/10.1111/j.1872-034X.2007.00186.x
Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res. 2007 Sep;37:S206-9. doi: 10.1111/j.1872-034X.2007.00186.x. PMID: 17877484.
Copy Download .nbib Format: NLM
Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.

Cancers

Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F.
PMID: 24213324
Cancers (Basel). 2012 Jun 05;4(2):549-65. doi: 10.3390/cancers4020549.

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced...

Cite
Di Maio M, Daniele G, Piccirillo MC, et al. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel). 2012;4(2):549-65doi: 10.3390/cancers4020549.
Di Maio, M., Daniele, G., Piccirillo, M. C., Giordano, P., Signoriello, G., Daniele, B., & Perrone, F. (2012). Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers, 4(2), 549-65. https://doi.org/10.3390/cancers4020549
Di Maio, Massimo, et al. "Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials." Cancers vol. 4,2 (2012): 549-65. doi: https://doi.org/10.3390/cancers4020549
Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F. Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel). 2012 Jun 05;4(2):549-65. doi: 10.3390/cancers4020549. PMID: 24213324; PMCID: PMC3712698.
Copy Download .nbib Format: NLM
Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study.

Endoscopy

Yang J, Chen YI, Friedland S, Holmes I, Paiji C, Law R, Hosmer A, Stevens T, Matheus F, Pawa R, Mathur N, Sejpal D, Inamdar S, Berzin TM, DiMaio CJ, Gupta S, Yachimski PS, Anderloni A, Repici A, James T, Jamil LH, Ona M, Lo SK, Gaddam S, Dollhopf M, Alammar N, Shieh E, Bukhari M, Kumbhari V, Singh V, Brewer O, Sanaei O, Fayad L, Ngamruengphong S, Shin EJ, Baron TH, Khashab MA.
PMID: 30769348
Endoscopy. 2019 Nov;51(11):C5. doi: 10.1055/a-0852-9243. Epub 2019 Feb 15.

No abstract available.

Cite
Yang J, Chen YI, Friedland S, et al. Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study. Endoscopy. 2019;51(11):C5doi: 10.1055/a-0852-9243.
Yang, J., Chen, Y. I., Friedland, S., Holmes, I., Paiji, C., Law, R., Hosmer, A., Stevens, T., Matheus, F., Pawa, R., Mathur, N., Sejpal, D., Inamdar, S., Berzin, T. M., DiMaio, C. J., Gupta, S., Yachimski, P. S., Anderloni, A., Repici, A., James, T., Jamil, L. H., Ona, M., Lo, S. K., Gaddam, S., Dollhopf, M., Alammar, N., Shieh, E., Bukhari, M., Kumbhari, V., Singh, V., Brewer, O., Sanaei, O., Fayad, L., Ngamruengphong, S., Shin, E. J., Baron, T. H., & Khashab, M. A. (2019). Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study. Endoscopy, 51(11), C5. https://doi.org/10.1055/a-0852-9243
Yang, Juliana, et al. "Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study." Endoscopy vol. 51,11 (2019): C5. doi: https://doi.org/10.1055/a-0852-9243
Yang J, Chen YI, Friedland S, Holmes I, Paiji C, Law R, Hosmer A, Stevens T, Matheus F, Pawa R, Mathur N, Sejpal D, Inamdar S, Berzin TM, DiMaio CJ, Gupta S, Yachimski PS, Anderloni A, Repici A, James T, Jamil LH, Ona M, Lo SK, Gaddam S, Dollhopf M, Alammar N, Shieh E, Bukhari M, Kumbhari V, Singh V, Brewer O, Sanaei O, Fayad L, Ngamruengphong S, Shin EJ, Baron TH, Khashab MA. Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study. Endoscopy. 2019 Nov;51(11):C5. doi: 10.1055/a-0852-9243. Epub 2019 Feb 15. PMID: 30769348.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 277 entries